JP5137491B2 - 水酸化アルミニウム吸着体の吸着性及び/又は溶出性の改変方法 - Google Patents
水酸化アルミニウム吸着体の吸着性及び/又は溶出性の改変方法 Download PDFInfo
- Publication number
- JP5137491B2 JP5137491B2 JP2007207429A JP2007207429A JP5137491B2 JP 5137491 B2 JP5137491 B2 JP 5137491B2 JP 2007207429 A JP2007207429 A JP 2007207429A JP 2007207429 A JP2007207429 A JP 2007207429A JP 5137491 B2 JP5137491 B2 JP 5137491B2
- Authority
- JP
- Japan
- Prior art keywords
- aluminum hydroxide
- ions
- ion
- elution
- adsorbent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 title claims description 113
- 238000000034 method Methods 0.000 title claims description 45
- 239000003463 adsorbent Substances 0.000 title claims description 40
- 238000010828 elution Methods 0.000 title claims description 38
- 150000002500 ions Chemical class 0.000 claims description 54
- 238000011282 treatment Methods 0.000 claims description 39
- 239000000725 suspension Substances 0.000 claims description 25
- 239000000427 antigen Substances 0.000 claims description 21
- 102000036639 antigens Human genes 0.000 claims description 21
- 108091007433 antigens Proteins 0.000 claims description 21
- 150000001450 anions Chemical class 0.000 claims description 19
- 239000000243 solution Substances 0.000 claims description 19
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 14
- 239000007853 buffer solution Substances 0.000 claims description 13
- 239000008055 phosphate buffer solution Substances 0.000 claims description 12
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 claims description 3
- 239000008351 acetate buffer Substances 0.000 claims description 3
- 239000011545 carbonate/bicarbonate buffer Substances 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims description 3
- CIJQGPVMMRXSQW-UHFFFAOYSA-M sodium;2-aminoacetic acid;hydroxide Chemical compound O.[Na+].NCC([O-])=O CIJQGPVMMRXSQW-UHFFFAOYSA-M 0.000 claims description 3
- -1 hydroxide ions Chemical class 0.000 claims description 2
- 229940024545 aluminum hydroxide Drugs 0.000 description 104
- 238000001179 sorption measurement Methods 0.000 description 33
- 239000000126 substance Substances 0.000 description 32
- 239000006228 supernatant Substances 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- 239000007864 aqueous solution Substances 0.000 description 14
- 239000000872 buffer Substances 0.000 description 13
- 238000000746 purification Methods 0.000 description 12
- 229940085991 phosphate ion Drugs 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 241000700605 Viruses Species 0.000 description 9
- 229960005486 vaccine Drugs 0.000 description 9
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- 229910052782 aluminium Inorganic materials 0.000 description 5
- 150000001768 cations Chemical class 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 239000012085 test solution Substances 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 3
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 3
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 3
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 150000002484 inorganic compounds Chemical class 0.000 description 3
- 229910010272 inorganic material Inorganic materials 0.000 description 3
- BPLYVSYSBPLDOA-GYOJGHLZSA-N n-[(2r,3r)-1,3-dihydroxyoctadecan-2-yl]tetracosanamide Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H](CO)[C@H](O)CCCCCCCCCCCCCCC BPLYVSYSBPLDOA-GYOJGHLZSA-N 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 102100023804 Coagulation factor VII Human genes 0.000 description 2
- 108010023321 Factor VII Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000012670 alkaline solution Substances 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000007922 dissolution test Methods 0.000 description 2
- 150000004679 hydroxides Chemical class 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000011126 aluminium potassium sulphate Nutrition 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- PCRDIRUKXOTDNN-UHFFFAOYSA-K aluminum;sodium;carbonate;hydroxide Chemical compound [OH-].[Na+].[Al+3].[O-]C([O-])=O PCRDIRUKXOTDNN-UHFFFAOYSA-K 0.000 description 1
- ZEMWIYASLJTEHQ-UHFFFAOYSA-J aluminum;sodium;disulfate;dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O ZEMWIYASLJTEHQ-UHFFFAOYSA-J 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 229910001422 barium ion Inorganic materials 0.000 description 1
- 229910001423 beryllium ion Inorganic materials 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- HFNQLYDPNAZRCH-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O.OC(O)=O HFNQLYDPNAZRCH-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 229940012413 factor vii Drugs 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 229940050271 potassium alum Drugs 0.000 description 1
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000011127 sodium aluminium sulphate Nutrition 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
Description
炭酸ナトリウム(日本薬局方(製造専用)乾燥炭酸ナトリウム: 高杉製薬社製)3.18gを生理食塩液(日本薬局方 大塚生食注:大塚製薬社製)200mLに撹拌しながら室温で溶解させ、A液:150mM 炭酸ナトリウム生理食塩液(pH11.9) とした。
上記で得られたAl濃度1.0mg/mLの水酸化アルミニウム懸濁液(pH8.2)を原液として用いて、リン酸イオン処理回数(曝露量)の異なる水酸化アルミニウムを調製した(表1)。リン酸イオン源として10mM リン酸緩衝液(PBS)(pH7.1)を用いた。
被吸着物質として、デンカ生研社の鶏卵培養によって得られたホルマリン不活化後のH5N1型鳥インフルエンザウイルスA/Vietnum株(RG株:全粒子、ウイルス抗原)を用いて、バッチ法により以下に示す吸着・溶出実験を行った。
A/Vietnum株被検液 (タンパク質濃度111μg/mL 10mM PBS:pH7.1、ウイルス抗原液)3.6mLを室温で撹拌しながら、上記で得られた滅菌水酸化アルミニウム再懸濁液(表1参照:Al 3.0mg/mL)0.4mLを添加して、ウイルス抗原液と水酸化アルミニウム懸濁液との混合液(タンパク質濃度100μg/mL、Al 0.3mg/mL)とした。該混合液をそのまま室温で15分間撹拌後、4℃で一晩撹拌を続け、吸着工程試験懸濁液4mLを得た。また、水酸化アルミニウム懸濁液0.4mLの代わりに10mM PBSを0.4mL用いて、上記と同様の方法により、水酸化アルミニウム無添加のA/Vietnum株対照試験液(タンパク質濃度100μg/mL 10mM PBS:pH7.1)4mLを調製した。
[吸着率(%)]=(([吸着対照上清中のタンパク質濃度]-[吸着試験上清中のタンパク質濃度])÷[吸着対照上清中のタンパク質濃度]) ×100
前記吸着工程で得られた吸着工程試験懸濁液280μLに、溶出液として1.0Mリン酸緩衝液(pH6.5)280μLを添加し、37℃で2時間(30分毎に10秒間転倒混和)加温した。その後、遠心分離(2000rpm,10分間,4℃)して上清(溶出試験上清)を得た。これについて、吸着工程と同様にタンパク質濃度測定(TCA-BCA法)を行った。また、A/Vietnum株対照試験液についても、吸着工程試験懸濁液と同様に溶出工程試験を行い、遠心分離後得られる上清(溶出対照上清)についてタンパク質濃度測定をした。
[溶出率(%)]=([溶出試験上清中のタンパク質濃度]÷[溶出対照上清中のタンパク質濃度])×100
表2から、リン酸イオン処理を行った水酸化アルミニウム(実施例1〜8)と、リン酸イオン非処理の水酸化アルミニウム(比較例1〜3)との間で、吸着担体として用いた場合の吸着率に著しい差はなかった。リン酸イオン処理により、被吸着物質の吸着阻害がほとんど生じていないといえる。
リン酸イオン処理を行った水酸化アルミニウム(実施例1〜8)は、リン酸イオン非処理の水酸化アルミニウム(比較例1〜3)より、いずれもほぼ2倍以上溶出率が向上していることが判った。また、リン酸イオン処理回数(曝露量)が増すにつれ、被吸着物質の溶出率も増大していた。
上記した担体調製例7(実施例4)の方法において、用いる緩衝液をPBSに代えて下記表3に記載する4種類の緩衝液(pH5.0〜9.5)とした他は同様の方法を行い、イオン処理した水酸化ナトリウム吸着体を得た(実施例9〜12)。
実施例9〜12の水酸化ナトリウム吸着体を用いて、上記と同様の方法により、ウイルスの吸着・溶出実験を行なった。結果を表3に示す。
Claims (4)
- 水酸化アルミニウム懸濁液又は固体状の水酸化アルミニウムを、少なくとも1種の陰イオンで処理することを含む、水酸化アルミニウム吸着体に吸着された抗原の溶出性の改変方法であって、前記陰イオンが、リン酸イオン、リン酸一水素イオン、リン酸二水素イオン、硫酸イオン、硫酸水素イオン、炭酸イオン、炭酸水素イオン及び水酸化物イオンから成る群より選択される少なくとも1種である方法。
- 前記処理は、前記水酸化アルミニウム懸濁液又は固体状の水酸化アルミニウムを、pH5.0〜9.5の、前記少なくとも1種の陰イオンを含む緩衝液と接触させることにより行なわれる請求項1記載の方法。
- 前記緩衝液は、リン酸緩衝液、酢酸緩衝液、トリス−塩酸緩衝液、グリシン−水酸化ナトリウム緩衝液及び炭酸−重炭酸緩衝液から成る群より選択される少なくとも1種である請求項2記載の方法。
- 前記緩衝液のpHが6.5〜8.0である請求項2又は3記載の方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007207429A JP5137491B2 (ja) | 2007-08-09 | 2007-08-09 | 水酸化アルミニウム吸着体の吸着性及び/又は溶出性の改変方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007207429A JP5137491B2 (ja) | 2007-08-09 | 2007-08-09 | 水酸化アルミニウム吸着体の吸着性及び/又は溶出性の改変方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009039656A JP2009039656A (ja) | 2009-02-26 |
JP5137491B2 true JP5137491B2 (ja) | 2013-02-06 |
Family
ID=40441003
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007207429A Active JP5137491B2 (ja) | 2007-08-09 | 2007-08-09 | 水酸化アルミニウム吸着体の吸着性及び/又は溶出性の改変方法 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5137491B2 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2021002257A1 (ja) * | 2019-07-04 | 2021-01-07 | ||
CN111000996A (zh) * | 2019-12-27 | 2020-04-14 | 深圳康泰生物制品股份有限公司 | 氢氧化铝佐剂及其制备方法与应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6046920A (ja) * | 1983-08-23 | 1985-03-14 | Miyazakiken | 天然ガス付随水中のリチウムの採取法 |
EP0294071A3 (en) * | 1987-06-03 | 1990-08-01 | Merck & Co. Inc. | Hepatitis b vaccines made with pre-formed aluminum hydroxide gels, and processes thereof |
JPH062580B2 (ja) * | 1988-11-14 | 1994-01-12 | 富田製薬株式会社 | ベーマイト状水酸化アルミニウム、その製造法及びそれを有効成分とする経口用リン酸イオン吸着剤 |
JP2003154001A (ja) * | 2001-11-20 | 2003-05-27 | Sentomedo:Kk | セリシン含有複合体およびその製造方法 |
-
2007
- 2007-08-09 JP JP2007207429A patent/JP5137491B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2009039656A (ja) | 2009-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016509068A (ja) | クロマチン欠損細胞培養採取物からの抗体のクロマトグラフィー精製 | |
JP2013500711A5 (ja) | ||
JP6720288B2 (ja) | ウイルス用無菌精製プロセス | |
TW201406956A (zh) | 類病毒顆粒之純化 | |
KR930001609B1 (ko) | 분리방법 및 분리제 | |
KR20150023297A (ko) | 고상 우레이드에 대한 생물학적 표적의 선택적 결합 | |
EP0698036A1 (en) | Process for removing endotoxins | |
EP3284778A1 (en) | Method for producing porous cellulose beads, and adsorbent using same | |
JP5137491B2 (ja) | 水酸化アルミニウム吸着体の吸着性及び/又は溶出性の改変方法 | |
CN113302197A (zh) | 包括使用活性炭材料的工序的纯化抗体的方法 | |
KR100266556B1 (ko) | 백일해균의 방어성분의 분리방법 | |
EP0252588A2 (en) | Process for the isolation and purification of P. falciparum CS protein expressed in recombinant E. coli, and its use as a vaccine | |
EP1507563B1 (en) | Endotoxin-binding ligands and their use | |
JP3148895B2 (ja) | 精製方法 | |
US6310186B1 (en) | Purification of biological preparations | |
JP5016830B2 (ja) | ペプチド精製物の製造方法 | |
JP2007238479A (ja) | ハイドロキシアパタイトに吸着された有機物の溶出方法及び該溶出方法を用いた有機物の精製方法 | |
US20160236171A1 (en) | Method for producing porous cellulose beads | |
ES2325584T3 (es) | Purificacion de variantes de her-2. | |
JP2009039038A (ja) | 被分離物質の分離方法及び精製方法 | |
JP4841749B2 (ja) | 精製抗原の製造法 | |
EP4361252A1 (en) | Commercial purification method for high-purity bacterial extracellular vesicles | |
TW201738257A (zh) | 標的蛋白質之純化方法 | |
JP6136236B2 (ja) | 組換えタンパク質の精製方法 | |
JP2007238474A (ja) | 難水溶性金属化合物に吸着した有機物の溶出方法及び該溶出方法を用いた有機物の精製方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100630 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20110512 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110524 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110725 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120417 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120615 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20121023 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121113 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5137491 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151122 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |